Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), are pleased to endorse the newly updated guidelines for hypertension management, issued by the European Society of Cardiology (ESC). The guidelines, presented at the ESC Congress on August 30, 2024, in London, include a significant endorsement for renal denervation (RDN) as a treatment option to improve uncontrolled hypertension.
The newly released “2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension” recommend renal denervation (RDN) as a safe and viable treatment option for patients with uncontrolled resistant hypertension or for those with uncontrolled hypertension and high cardiovascular risk who prefer RDN over additional medication.
Hypertension, commonly known as high blood pressure, affects more than one billion individuals globally. Often referred to as the “silent killer” due to its lack of visible symptoms, untreated hypertension can result in serious health issues over time. Despite lifestyle changes and the use of medications, around 75% of treated patients remain with uncontrolled hypertension.
Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system is an innovative ultrasound-based technology designed to lower blood pressure by targeting overactive sympathetic nerves around the renal arteries. It is specifically for patients whose hypertension is not adequately managed by medication alone. The ESC guidelines now acknowledge renal denervation as an essential option for these patients.
Prof. Dr. Michael Böhm, Cardiologist and Director of the Internal Medicine III Clinic at Saarland University Hospital in Homburg, expressed his thoughts on the updated guidelines, stating: “This recommendation from the ESC represents a significant advancement for patients in need of an additional safe and effective option to control hypertension when lifestyle modifications and medications fall short. The recommendation follows strong evidence from randomized sham-controlled trials demonstrating the efficacy and safety of renal denervation.”
Dr. Böhm further explained, “The ESC advises that RDN be performed in medium-to-high volume centers following multidisciplinary assessment and a thorough discussion of risks and benefits with the patient. Now, the task ahead is to implement these guidelines into clinical practice and offer this solution to the patients who need it.”
Recor has successfully completed three global, independently powered sham-controlled randomized clinical trials – RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II – involving more than 500 patients with uncontrolled hypertension. These studies consistently met their primary endpoints, showcasing significant reductions in blood pressure and positive safety outcomes. The Paradise uRDN system received CE mark approval in 2012, and Recor continues to collaborate with the European cardiology community to bring this groundbreaking therapy to patients.
Lara Barghout, President and CEO of Recor, expressed her enthusiasm for the updated ESC recommendations: “We are thrilled that the ESC guidelines now recommend renal denervation as an effective treatment for uncontrolled hypertension. The global need to address hypertension remains urgent, and we are dedicated to transforming hypertension treatment with the proven benefits of Paradise ultrasound RDN.”
As Recor Medical continues to expand the adoption of its cutting-edge technology, the growing endorsement from medical societies such as the ESC offers further validation of the company’s mission to revolutionize hypertension treatment.